This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dever, L. L.
Right arrow Articles by Barbour, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dever, L. L.
Right arrow Articles by Barbour, A. G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1999, p. 1773-1775, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

In Vitro Activities of the Everninomicin SCH 27899 and Other Newer Antimicrobial Agents against Borrelia burgdorferi

Lisa L. Dever,1,* Christine V. Torigian,1 and Alan G. Barbour2

Medical Service, Veterans Affairs New Jersey Health Care System, East Orange, and Department of Medicine, UMDNJ-New Jersey Medical School, Newark, New Jersey,1 and Departments of Microbiology and Molecular Genetics and Medicine, University of California Irvine College of Medicine, Irvine, California2

Received 30 October 1998/Returned for modification 15 March 1999/Accepted 19 April 1999

The in vitro activity of the everninomicin antibiotic SCH 27899 against 17 isolates of Borrelia spp. was investigated. MICs ranged from 0.06 to 0.5 µg/ml. Time-kill studies with the B31 strain of B. burgdorferi demonstrated >= 3-log10-unit killing after 72 h with concentrations representing four times the MIC. The in vitro activity of four other newer antimicrobial agents, meropenem, cefepime, quinupristin-dalfopristin, and linezolid, was also tested against the B31 strain. Meropenem was the most potent of the latter agents, with an MIC of 0.125 µg/ml.

* Corresponding author. Mailing address: Medical Service (111-ID), VA Medical Center, 385 Tremont Ave., East Orange, NJ 07018. Phone: (973) 676-1000, ext. 2156. Fax: (973) 677-4458. E-mail: dever.lisa{at}east-orange.va.gov.

Antimicrobial Agents and Chemotherapy, July 1999, p. 1773-1775, Vol. 43, No. 7
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Butaye, P., Devriese, L. A., Haesebrouck, F. (2003). Antimicrobial Growth Promoters Used in Animal Feed: Effects of Less Well Known Antibiotics on Gram-Positive Bacteria. Clin. Microbiol. Rev. 16: 175-188 [Abstract] [Full Text]  
  • Pavia, C. S., Wormser, G. P., Nowakowski, J., Cacciapuoti, A. (2001). Efficacy of an Evernimicin (SCH27899) In Vitro and in an Animal Model of Lyme Disease. Antimicrob. Agents Chemother. 45: 936-937 [Abstract] [Full Text]  
  • Tanaka, K., Kato, N., Watanabe, K. (2000). In vitro activity of an evernimicin derivative, SCH27899, against anaerobic bacteria and Propionibacterium acnes. J Antimicrob Chemother 46: 465-469 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»